Particularly, in two non-small-cell lung cancer models, the antiproliferative effect was accompanied by the inhibition of the CK2-dependent canonical NF-kB pathway, with reduced REL A/p65 nuclear levels and conditionally reduced NF-kB transcriptional activity [56]. The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.